THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Of ...

THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. About Autonomix Medical, Inc. For more information, visit autonomix.com and connect with the Company on ...

For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pa ...

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDAcleared ablation technology from RF Innovations, Inc. For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. Ab ...

Core Viewpoint - Autonomix Medical (NASDAQ:AMIX) experienced significant stock volatility, with a notable rally followed by a decline in share price due to market reactions and company announcements [1][6]. Group 1: Stock Performance - AMIX stock rallied 130% during normal trading hours yesterday, with approximately 152 million shares traded, significantly above its daily average of about 3 million shares [5]. - Following the rally, AMIX stock is down 16.7% as of Tuesday morning, indicating a correction after the previous day's gains [6]. Group 2: Company Developments - Autonomix Medical announced a definitive agreement with RF Innovations to license the intellectual property of its Apex 6 Radiofrequency Generator, expected to be completed by the end of the month [2]. - The company provided updates on its pancreatic cancer pain management device, reporting positive results from a clinical trial that utilizes radiofrequency (RF) ablation to alleviate pain in pancreatic cancer patients [4].

Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. "This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management," stated President and CEO Brad Hauser. At the same time, Autonomix is a speculative enterprise. The company made its public ...

RF Innovations' Apex 6 Generator aligns with specifications required for Autonomix's ablation system and facilitates ongoing development Transaction further reinforces Autonomix's FDA regulatory pathway THE WOODLANDS, TX, July 15, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered ...

Financial Performance and Funding - Future financial performance is dependent on successfully raising additional equity or debt financing to fund operations[21]. - The company currently has no source of product sales revenue, indicating a need for successful commercialization of product candidates[21]. Competition and Market Risks - The company is facing competition from existing products and potential new products that may emerge in the market[21]. - General economic uncertainty may adversely affect spending on medical procedures, impacting the company's market[21]. Regulatory and Compliance Risks - There are risks associated with compliance to U.S. and foreign regulatory requirements, which could limit or withdraw marketing approvals[21]. Operational Dependencies - The company is reliant on third-party supply and manufacturing partners for materials and components necessary for research and development[21]. - Future growth is contingent upon the ability to attract and retain key management and technical personnel[21]. Financial Reporting and Stockholder Concerns - The company has identified material weaknesses in its control over financial reporting, which could impact financial performance[21]. - The company is exposed to volatility in the market price of its stock, which could affect investor confidence[21]. - Potential dilution to current stockholders may occur from the issuance of equity awards[21].